Gustavo Viani: Is this enough to make SBRT the go-to option for inoperable HCC?
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, University of Sao Paulo, posted on X about recent paper by Naoko Sanuki et al., titled “Final results of a multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma (the STRSPH study)” published on Red Journal.
Authors: Naoko Sanuki, Tomoki Kimura, Atsuya Takeda, Keisuke Ariyoshi, Shunsuke Oyamada, Takuhiro Yamaguchi, Yuichiro Tsurugai, Yoshiko Doi, Masaki Kokubo, Toshiyuki Imagumbai, Norio Katoh, Takahisa Eriguchi, Satoshi Ishikura
“Is this enough to make SBRT the go-to option for inoperable HCC? Or will it stay in the shadow of other treatments.
Objective:
Assess SBRT for solitary HCC in patients unfit for surgery or ablation
Methods
•Trial: Multicenter, phase II
•Participants: 34 with untreated solitary HCC (1–5 cm)
•Treatment: 40 Gy/5 fractions
Outcomes:
•3-year OS: 82%
•3-year LC: 93%
•Toxicity: Mild/no Grade 5 events
Conclusion:
SBRT offers a safe, effective alternative for HCC when curative treatments aren’t possible.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023